In de novo PD patients, as in HC, alexithymia was associated with depression and impulsivity, but these neuropsychiatric features were not associated. In addition to the known association between alexithymia and depression2 in both groups, impulsivity was predicted by alexithymia, and, considering TAS-20 factors, only by the TAS-20 F-1 factor. This finding is partially at variance with findings reported in a study with healthy subjects,3 in which impulsivity was not found to be associated with the TAS-20 total score, in contrast with our study, but only with the TAS-20 F-1 factor, as we found for PD and HC. Therefore, alexithymic difficulty in identifying one's own feelings could factor into situations where there is rapid respond to cues for potential reward without much planning or deliberation and without consideration of potential punishment or loss of reward, as defines impulsivity.4 Considering that dopamine agonists adopted to treat PD motor symptoms may increase impulsivity and the risk of developing impulse-control disorders,5 the clinical implication of this finding is that the presence of alexithymic features, especially the difficulty in identifying one's own feelings, could represent a risk factor for the development of impulse-control disorders when patients are treated with dopamine agonists. This hypothesis, which deserves further empirical investigation, highlights the importance of assessing multiple mental health domains, including alexithymia, in de novo PD patients, in order to prevent and/or better manage possible neuropsychiatric side effects of dopaminergic drugs.